Evidence map›Paper›PMID 37555912›Full record

ArticleClinical and experimental medicine2023

Characteristics and classification of first primary cancer patients with second primary cancer: a population-based cohort study.

Zhaohui Ruan, Yuetong Zhang, Zhaozhi Li, Jiaxin Jiang, Wei Luo, Qi Quan, Zihao Xu, Jinju Lei, Roujun Peng

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical and experimental medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Zhaohui Ruan *VIP Section Department, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Dongfeng East Road, Guangzhou, 510060, People's Republic of China.
Yuetong Zhang *Department of Experimental Research, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Zhaozhi Li *Computational Biology, Cornell University, Ithaca, NY, USA.
Jiaxin JiangVIP Section Department, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Dongfeng East Road, Guangzhou, 510060, People's Republic of China.
Wei LuoVIP Section Department, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Dongfeng East Road, Guangzhou, 510060, People's Republic of China.
Qi QuanVIP Section Department, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Dongfeng East Road, Guangzhou, 510060, People's Republic of China.
Zihao XuVIP Section Department, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Dongfeng East Road, Guangzhou, 510060, People's Republic of China.
Jinju LeiCancer Center, Renmin Hospital of Wuhan University, No. 99 ZhangZhiDong Street, Wuchang District, Wuhan, 430060, Hubei, People's Republic of China. leijinju2204@126.com.
Roujun PengVIP Section Department, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Dongfeng East Road, Guangzhou, 510060, People's Republic of China. pengrj@sysucc.org.cn.
Sun Yat-sen University · CNCornell University · USWuhan University · CN

Funding

Basic and Applied Basic Research Foundation in Guangdong Province 2022A1515012387
6 · The paper itself

Abstract

Cancer survivors have an increased risk of developing subsequent primary tumors. However, the characteristics of first primary cancers (FPCs) with various types of second primary cancers (SPCs) are poorly understood, which hinders screening strategies. We analyzed data from 1,893,258 patients from the Surveillance, Epidemiology, and End Results (SEER) database to characterize and classify of FPC patients with subsequent SPCs at the pan-cancer level. In total, 3% of patients had SPC, with varied incidence rates observed depending on the types of FPC. Their onset patterns of SPC and diversity of SPC varied. Based on the diversity of the high-incidence sites of SPC, we classified FPCs into two categories: FPCs that require whole-body screening and those that need screening of particular body parts. Moreover, according to the different timing of high incidence of SPCs, our system classifies FPCs into two subtypes: FPCs that require long-term monitoring for the occurrence of SPCs and those that require screening at specific time points for SPCs. Furthermore, we identified 11 anatomical sites where over half of FPC types are prone to SPC occurrence at these locations. The risk factors for SPC occurrence in different FPC types and prognostic factors were also elucidated. Overall, we characterize and classify of FPC patients with subsequent SPCs at the pan-cancer level, which can guide the development of distinct screening strategies for each FPC type.

Indexed as

NeoplasmsNeoplasms, Second PrimaryCohort StudiesHumansIncidenceRisk FactorsFirst primary cancersPan-cancer analysisSecond primary cancers

Identifiers

PMID37555912
OpenAlexW4385684766

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.